for medical use
of EMOKSIPIN medicine
the Trade name
Mezhdunarodnoye the unlicensed name
Is not present
the Dosage form
of the Drop eye 1% 5 ml
1 ml of drops contains
active agent – emoksipin 0.010 g,
excipients: sodium sulfite anhydrous, Natrium benzoicum, potassium dihydrophosphate, phosphate dinatrium dodecahydrate, water for injections.
Transparent colourless or with a yellowish shade liquid
Drugs for treatment of diseases of eyes others.
The code of automatic telephone exchange S01XA
Pharmacokinetics Therapeutic Concentration properties in tissues of an eye is reached at single burying. Emoksipin does not collect in bodies and fabrics. Within the first two hours after use the concentration of an emoksipin in blood quickly decreases, in 24 hours drug in blood is absent. In eye tissues the concentration of an emoksipin is higher, than in blood.
Emoksipin’s pharmacodynamics – a vasoprotective, reduces permeability of a vascular wall, is inhibitor of free radical processes, anti-hypoxanthomas and antioxidant, reduces viscosity of blood and aggregation of thrombocytes. Has retinoprotektorny properties, promotes resorption of intraocular hemorrhages, improves microcirculation of an eye.
– hemorrhages in an anterior chamber of an eye
– treatment and prevention of inflammations and burns of a cornea
– protection of a cornea when carrying contact lenses
– dystrophic changes of a retina in case of shortsightedness of high degree
– a diabetic retinopathy
the Route of administration and doses
use Drug at adults in the form of instillations in a conjunctival sac on 1-2 drops 2 – 3 times a day. Duration of a course of treatment depends on a course of the disease (usually makes 3 – 30 days) and is defined by the doctor. In the presence of indications and good tolerance duration of a course of treatment can be up to 6 months.
If necessary repeated courses of treatment are carried out with an interval of 4 – 6 months.
– burning sensation, an itching
– short-term reddening of a conjunctiva
– consolidation of paraorbital fabrics (resolves independently)
– the increased individual sensitivity to an emoksipin
– children’s and teenage age up to 18 years
of Negative manifestations at use of an emoksipin against the background of therapy by other medicines is not described.
Solution should not be mixed with other medicines. In need of simultaneous use of other ophthalmologic medicines (eye drops, etc.) emoksipin apply the last, after full absorption of the previous drug (not less than in 10-15 minutes).
instructions Lactation Period Use in the period of a lactation perhaps if the expected advantage for a matenra exceeds potential risk for the child.
Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
At use of eye drops of an emoksipin perhaps short-term burning sensation and the nagger. It is necessary to refrain from control of motor transport within 15-20 minutes after drug use. Drug does not influence the speed of psychomotor reactions.
of the Phenomena of overdose at use of eye drops of an emoksipin it is not described.
A form of release and packing
of the Drop eye 1% on 5 ml in bottles. The bottle together with the instruction for medical use in the state and Russian languages is placed in a pack cardboard.
To Store storage conditions in the place protected from light, at a temperature from + 15 °C to + 25 °C.
To store a bottle after the first opening at a temperature not above + 25 °C within 4 weeks.
To store out of children’s reach!
not to apply a period of storage after expiry date.
According to the prescription
RUP producer of Belmedpreparata,
Republic of Belarus, 220007, Minsk, Fabritius St., 30,
t. / f.: (+375 17) 220-37-16,
The address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products
of TsentrAziyaPharm LLP,
050030, Republic of Kazakhstan, Almaty, Suyunbaya Ave., 290
ph. 727 290 27 80, 727 385 04 00,